Keith Katkin

Keith A. Katkin is currently Chairman at Eledon Pharmaceuticals, Inc. since 2017.
He is an Independent Director at Syndax Pharmaceuticals, Inc. since 2017 and at Emergent BioSolutions, Inc. since 2022.
He serves as Director at Brain Injury Association of America, Inc. and Transposon Therapeutics, Inc. Formerly, Mr. Katkin was President, Chief Executive Officer & Director at Avanir Pharmaceuticals, Inc. from 2007 to 2016.
He was President, Chief Executive Officer & Director at Urovant Sciences, Inc. from 2017 to 2020 and Chief Executive Officer & Director at Urovant Sciences Ltd. from 2018 to 2020.
He served as Chairman at Otic Pharma Ltd. from 2015 to 2017.
He was an Independent Director at Rigel Pharmaceuticals, Inc. from 2015 to 2022 and Independent Class III Director at Carbylan Therapeutics, Inc. from 2014 to 2016.
He was Director at MC10, Inc. and Director at CoverMyMeds LLC from 2015 to 2017.
He held the position of Vice President-Commercial Development at Peninsula Pharmaceuticals, Inc. from 2004 to 2005.
Education includes an undergraduate degree from Indiana University in 1993 and an MBA from UCLA Anderson School of Management.